Several individuals enrolled in a phase 3 trial for Eli Lilly's (NYSE:LLY) next-generation obesity drug, retatrutide, say ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Two healthcare stocks that may or may not be boring, but that regardless look like strong growth stocks to invest in this ...

Nearly a year ago, Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results from a clinical trial with an experimental weight loss ...

In June 2023, Lilly reported phase 2 trial results that showed retatrutide reduced body weight by 24.2% after 48 weeks. As a well-established pharmaceutical giant, Lilly can use its immense ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound ... its next-generation obesity drug retatrutide later this year, a few ...

We list the best Gantt chart software, to make it simple and easy to better visualize and manage progress when dealing with larges projects. Gantt chart software can be a powerful weapon in a ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...